Preview

Rational Pharmacotherapy in Cardiology

Advanced search

USE OF ROSUVASTATIN AS A GEROPROTECTOR IN PEOPLE ENGAGED IN NATURAL GAS PRODUCING

https://doi.org/10.20996/1819-6446-2011-7-4-447-451

Full Text:

Abstract

Background. Prolong contact with manufacturing factors of gas producing, in particular hydrogen sulfide, results in dysfunction of various organs and systems, including immune system, which is involved in regulation of the aging process activity. Absence of effective geropreventive means creates the need for pathogenetic way for aging process deceleration. Aim. To study the geroprotective properties of rosuvastatin in respect of people engaged in the gas producing. Material and Methods. The male workers (n=100) of the company “Gazprom dobycha Astrakhan” were examined. Evaluation of biological age by the method of Chebotarev D.F ., determination of p53 protein and interleukin-8, 10, 18 concentrations by solid phase enzyme immunoassay were performed before treatment start and after 18 months of rosuvastatin taking. Results. Rosuvastatin therapy in dose of 5 mg/day resulted in the reduction in atherogenic lipids, pro-inflammatory cytokine - interleukin-8 and marker of apoptosis - protein p53 as well as aging rate slowdown. Conclusion. Pathogenic method of geroprevention with rosuvastatin 5 mg/day was proposed for people engaged in gas producing.

About the Authors

A. T. Abdrashitova
Astrakhan State Medical Academy Non-governmental Health Care Institution «Medical and Sanitary Unit»
Russian Federation


T. N. Panova
Astrakhan State Medical Academy
Russian Federation


I. A. Belolapenko
Non-governmental Health Care Institution «Medical and Sanitary Unit»
Russian Federation


M. V. Frenkel
Non-governmental Health Care Institution «Medical and Sanitary Unit»
Russian Federation


References

1. Anisimov V.N. Molecular and physiological mechanisms of aging. St. Petersburg:Nauka; 2003. Russian (Анисимов В.Н. Молекулярные и физиологические механизмы старения. СПб: Наука; 2003).

2. Dontsov V.I., Krutko V.N., Podkolzin A.A. Fundamental mechanisms of aging prevention. Moscow: Bioinformservis; 2002. Russian (Донцов В.И., Крутько В.Н., Подколзин А.А Фундаментальные механизмы геропрофилактики. М: Биоинформсервис; 2002).

3. Frolkis V.V., Muradian H.K. Aging. Evolution and life extension. Kiev: Naukova Dumka,1992. Russian (Фролькис В.В., Мурадян Х.К. Старение. Эволюция и продление жизни. Киев: Наукова думка; 1992).

4. Moskalev A.A. Aging and genes. St. Petersburg: Nauka, 2008. Russian (Москалев А.А. Ста-рение и гены. СПб: Наука; 2008).

5. Hanson K.P. The role of apoptosis in aging and age pathology. Advances in Gerontology 1999; 3:103-110. Russian (Хансон К.П. Роль апоптоза в старении и возрастной патологии. Успехи геронтологии 1999; 3:103-110).

6. Pristrom M.S., Sushinskiy V.E., Semenenkov I.I., Vorob'eva E.P. Physiological andpremature aging. Place of statins in preventing premature aging. Meditsinskie novosti 2009; 6: 25-

7. Russian (Пристром М.С., Сушинский В.Э., Семененков И.И., Воробьёва Е.П. Старение физиологическое и преждевременное. Место статинов в предупреждении преждевременного старения. Медицинские новости 2009; 6: 25-30).

8. Atroshchenko E.S. Statins and coronary heart disease. Minsk: OOO Belprint; 2007. Russian (Атрощенко Е.С. Статины и коронарная болезнь сердца. Минск: ООО «Бел-принт»; 2007).

9. Martin G., Duez N., Blanquart C. et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apo-A-I. J Clin Invest 2001; 107(11):1423-1432.

10. Belenkov Yu.N., Tatenkulova S.N., Mareev V.Yu. et al. Immunocorrecting properties of statins in the treatment of dilated cardiomyopathy. Serdechnaya nedostatochnost' 2008; 9 (6): 268-273. Russian. (Беленков Ю.Н., Татенкулова С.Н., Мареев В.Ю. и др. Иммунорегулирующие свойства статинов в лечении дилатационной кардиомиопатии. Сердечная недостаточность 2008; 9 (6): 268-273).

11. Ridker P.M., Danielson E., Fonseca F.A. et al., on behalf of the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.

12. Avaliani S.L., Revich B.A., Zakharov V.M. Regional environmental policies. Monitoring zdorov'ya cheloveka i zdorov'ya sredy. Moscow: TSPER; 2001. Russian (Авалиани С.Л., Ревич Б.А., Захаров В.М. Региональная экологическая политика. Мониторинг здоровья человека и здоровья среды. М.: ЦПЭР; 2001).

13. Polunin, I.N., Asfandiyarov R.I., Trizna N.N. Toxic pulmonary edema in acute poisoning with hydrogen sulfide gas. Astrakhan: AGMA, 1999. Russian (Полунин И.Н., Асфандияров Р.И., Тризно Н.Н. Токсический отек легких при остром отравлении сероводородсодержащим газом. Астрахань: АГМА; 1999).

14. Chebotarev D.F., editor. Gerontology and Geriatrics, 1984. Yearbook: biological age, heredity and aging. Kiev; 1984. Russian (Чеботарев Д.Ф., редактор. Геронтология и гериатрия, 1984. Ежегодник: биологический возраст, наследственность и старение. Киев;1984).

15. Pashkov O.L., Shishlo L.M., Prokhorov V.I. The study of the levels of soluble TNF receptorp55 and IL-8 in blood and urine of patients with bladder cancer. Siberian Journal of Oncology 2008; Suppl 1: 104-105. Russian (Пашкова О.Л., Шишло Л.М., Прохорова В.И. Изучение уровней растворимого рецептора ФНО р55 и интерлейкина-8 в крови и моче больных раком мочевого пузыря. Сибирский онкологический журнал 2008; Приложение 1: 104-105).

16. Yarilin A.A. Apoptosis: the nature of the phenomenon and its role in health and disease. In: Frost B.B., editor. Actual problems of pathophysiology. Moscow: Medicine; 2001.P.13-

17. Russian (Ярилин А.А. Апоптоз: природа феномена и его роль в норме и при патологии. В: Мороз Б.Б., редактор. Актуальные проблемы патофизиологии. М.: Медицина; 2001. С. 13-56).


For citation:


Abdrashitova A.T., Panova T.N., Belolapenko I.A., Frenkel M.V. USE OF ROSUVASTATIN AS A GEROPROTECTOR IN PEOPLE ENGAGED IN NATURAL GAS PRODUCING. Rational Pharmacotherapy in Cardiology. 2011;7(4):447-451. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-4-447-451

Views: 356


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)